Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

BACKGROUND: With the advent of immune-checkpoint inhibitors and targeted treatments (TT), there have been unprecedented response rates and survival in advanced melanoma, but the optimal sequencing of these two treatments modalities is unknown. Combining or sequencing these agents could potentially r...

Descripción completa

Detalles Bibliográficos
Autores principales: Naqash, Abdul Rafeh, File, Danielle M., Ziemer, Carolyn M., Whang, Young E., Landman, Paula, Googe, Paul B., Collichio, Frances A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323838/
https://www.ncbi.nlm.nih.gov/pubmed/30621779
http://dx.doi.org/10.1186/s40425-018-0475-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6323838/
https://www.ncbi.nlm.nih.gov/pubmed/30621779
http://dx.doi.org/10.1186/s40425-018-0475-y

Ejemplares similares